Clearside Biomedical (CLSD)
Wedbush analyst Liana Moussatos reiterated a Buy rating on Clearside Biomedical today and set a price target of $4. The company’s shares closed yesterday at $1.30, close to its 52-week low of $0.99.
According to TipRanks.com, Moussatos is ranked 0 out of 5 stars with an average return of -8.8% and a 33.5% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical Inc., Allena Pharmaceuticals Inc, and Aquestive Therapeutics Inc.
Clearside Biomedical has an analyst consensus of Moderate Buy, with a price target consensus of $4.
Pacific Biosciences (PACB)
Cantor Fitzgerald analyst Jordan Abrams maintained a Hold rating on Pacific Biosciences today and set a price target of $8. The company’s shares closed yesterday at $7.37, close to its 52-week high of $7.84.
“We think PACB’s long-read next-generation sequencing platform is the industry standard for deep genomic analysis in human, plant, and animal genomes, as well as RNA. The company has seen mixed revenue performance over the past three years, but we think PACB is getting close to an inflection point, which we think the Street is missing. We see the path to revenue acceleration as multifactorial. These include the launch of its 8 million ZMW SMRT cell, increased penetration of the plant and animal sequencing market, and significant sequencing cost reduction per human genome enabling PACB to become a more mainstream player in human genomics.”
Abrams has an average return of 59.4% when recommending Pacific Biosciences.
According to TipRanks.com, Abrams is ranked #4437 out of 5197 analysts.
Currently, the analyst consensus on Pacific Biosciences is a Hold with an average price target of $8.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.